A new combination of drugs could help delay the advancement of a deadly form of prostate cancer in those with an advanced form of the disease, new research has found. The “striking” findings showed an ...

An individual-patient meta-analysis sheds light on the optimal duration of androgen deprivation therapy in men with prostate cancer on definitive radiotherapy.

Risk of death and cause of death 30 years after diagnosis as a proportion of 100 men. Grey figures indicate the proportion of men alive after 30 years, blue figures the proportion of men who died of ...

A novel long-term prediction model showed promise at estimating the risk for dying of prostate cancer, an analysis published in Annals of Internal Medicine indicated.“We have developed a tool that can ...

People with localized prostate cancer treated according to guidelines developed by an international panel of doctors are more likely to die of something other than the disease, new research shows. A ...

Study results are based on Surveillance, Epidemiology, and End Results-Medicare data for 166,581 patients receiving surgery or radiation for localized prostate cancer.

Cancer survival in the U.S. has climbed to 70%, reflecting major advances in treatment, early detection and personalized care, new data show.

Investigators evaluated the benefit of leuprorelin immediately after radical prostatectomy for prostate cancer in patients ...

The phase 3 NRG GU-005 trial did not show a DFS benefit for SBRT vs IMRT in intermediate-risk prostate cancer, but SBRT decreased rectal toxicity. Stereotactic body radiation therapy (SBRT) preserves ...

Prostate cancer is the most common cancer in Australia, with about 26,000 men diagnosed per year. The majority (more than 85%) are aged over 60. Subscribe to our newsletter for the latest sci-tech ...